재고 위치

New Jersey, USA
Czech Republic, EU
Mumbai, India

* 재고 가용성에 따라 다름

Documentation

MSDS 다운로드

샘플 COA 다운로드

포함 사항: HPLC, MASS/LC-MS, 1H NMR, FT-IR, 함량, 구조 규명 보고서(SER), 그리고 제품에 따라 추가 분석 데이터가 제공됩니다.

Abiraterone Acetate-5,6-Epoxide

● Under Development

카탈로그 번호:	VL830024
CAS 번호:	N/A
분자식:	C26H33NO3
분자량:	407.55 g/mol

무엇을 도와드

RFQ 목록에 추가

에 대한 추가 정보 Abiraterone Acetate-5 | 6-Epoxide

모약물

Abiraterone

IUPAC명

(3S, 6aS, 6bS, 9aS, 11aS, 11bR)-9a, 11b-dimethyl-9-(pyridin-3-yl)-1, 2, 3, 4, 5a, 6, 6a, 6b, 7, 9a, 10, 11, 11a, 11b-tetradecahydrocyclopenta[1, 2]phenanthro[8a, 9-b]oxiren-3-yl acetate

약전 동의어

N/A

Other Synonyms

N/A

SMILES

CC(O[C@H](C1)CC[C@]2(C)[C@@]3([H])CC[C@@](C(C4=CC=CN=C4)=CC5)(C)[C@]5([H])[C@]3([H])CC6C21O6)=O

InChI

InChI=1S/C26H33NO3/c1-16(28)29-18-8-11-25(3)22-9-10-24(2)20(17-5-4-12-27-15-17)6-7-21(24)19(22)13-23-26(25,14-18)30-23/h4-6,12,15,18-19,21-23H,7-11,13-14H2,1-3H3/t18-,19-,21-,22-,23?,24+,25+,26?/m0/s1

설명

The compound Abiraterone Acetate-5,6-Epoxide is a thoroughly characterized reference standard that complies with rigorous regulatory guidelines, including those from USP, EMA, JP, and BP. It is ideal for critical applications such as analytical method development, method validation (AMV), and quality control (QC), especially in the production of Abiraterone. Designed to support both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA), this product delivers the precision required for reliable results. Additionally, it includes a detailed Structure Elucidation Report (SER), ensuring accuracy and dependability for advanced analytical purposes. Abiraterone Acetate-5,6-Epoxide or (3S,6aS,6bS,9aS,11aS,11bR)-9a,11b-dimethyl-9-(pyridin-3-yl)-1,2,3,4,5a,6,6a,6b,7,9a,10,11,11a,11b-tetradecahydrocyclopenta[1,2]phenanthro[8a,9-b]oxiren-3-yl acetate, that inhibits 17a-hydroxylase CYP17 and is used in the treatment of prostate cancer.

References

Goldberg, Tamara, and Evangelina Berrios-Colon. â€œAbiraterone (Zytiga), a Novel Agent for the Management of Castration-Resistant Prostate Cancer.â€ Pharmacy and Therapeutics, vol. 38, no. 1, 1 Jan. 2013, pp. 23â€“26, www.ncbi.nlm.nih.gov/pmc/articles/PMC3628169/.